Anti-obesity drug Mounjaro is set to rack up global sales worth nearly £22bn a year by the end of the decade. But Donald ...

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...

On an investment spree with billions of dollars’ worth of projects ongoing globally, Indianapolis-based Eli Lilly and Company ...

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...

AnalytiXIN has launched a consortium designed to give Indiana researchers better access to health care data—potentially ...

Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new Novo Nordisk drug ...